Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Cladribine
Treatment of neuromyelitis optica.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
Good Early Results for HERV Suppressor in MS
Pharmacokinetic properties and metabolism of idebenone.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
First proof for rituximab in IgG4-related disease
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Colestipol May Quickly Eliminate Teriflunomide
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Phase 3 Study of RPC1063 in Relapsing MS
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Company restores access to multiple sclerosis drug after pressure from neurologists.

Pages